Category

Press Releases

VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

By | Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to...
Read More

VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine Candidate Targeting COVID-19, SARS, and MERS

By | Pan-Coronavirus, Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus...
Read More

VBI Vaccines Appoints Damian Braga to Board of Directors

By | Press Releases
Former Senior Vice President, Global Commercial Operations of Sanofi Pasteur, the human vaccines business of the Sanofi Group, brings broad commercial expertise to support VBI’s regulatory-stage trivalent hepatitis B vaccine, Sci-B-Vac® VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company...
Read More